PAN Min,ZHANG Tian-jing,CHANG Shuang,FENG Xiao-xia,WEI Wei,LI Jun,ZHAO Hong-mei,FEI Guang-he,LI Jia-bin,CHEN Fei-hu,DAI Min,MENG Xiao-ming,WANG Hua,XIANG Yi,CAO Meng-shu,CHEN Xiao-yang,YE Xian-wei,XU Du-juan,HU Xiao-wen,JIANG Ling,WANG Chang-hui,WANG Yong-zhong,LIU Hao,XIE Hai-tang,FANG Ping,QIAN Zhen-dong,TANG Chao,YANG Gang,TENG Xiao-bao,QIAN Chao-xia,DING Guo-zheng,SUN Yan,FAN Xiao-yun,ZHANG Ling-ling

Abstract:COVID-19 has been prevalent for three years. The virulence of SARS-CoV-2 is weaken as it mutates continuously. However, elderly patients, especially those with underlying diseases, are still at high risk of developing severe infections. With the continuous study of the molecular structure and pathogenic mechanism of SARS-CoV-2, antiviral drugs for COVID-19 have been successively marketed, and these anti-SARS-CoV-2 drugs can effectively reduce the severe rate and mortality of elderly patients. This article reviews the mechanism, clinical medication regimens, drug interactions and adverse reactions of five small molecule antiviral drugs currently approved for marketing in China, so as to provide advice for the clinical rational use of anti-SARS-CoV-2 in the elderly.

Treatment Advice of Small Molecule Antiviral Drugs for Elderly COVID-19